Ariad Pharmaceuticals has posted a net loss of $4.7 million, or $0.17per share, for the second quarter of 2001, an increase of 46.9% compared with the like, year-earlier period. Revenues fell to just under $400,000 from $470,000.
The firm's R&D expenses increased 27% to $3.7 million, while general and administrative costs soared 96.5% to $1.3 million. Ariad ended the quarter with $45.3 million in cash and equivalents. Chief executive Harvey Berger said that "the accelerated development of our lead product candidates and the commercialization of our technology platforms and intellectual property portfolio continue to be our two strategic priorities." The firm says it is developing a pipeline of "innovative pharmaceutical products" to treat osteoporosis, cancer, anemia and graft-versus-host disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze